

**WRITTEN OPINION OF THE  
INTERNATIONAL SEARCHING AUTHORITY**

International Application No.

**PCT/AU2008/XXXXXX**

**Box No. V Reasoned statement under Rule 43bis.1(a)(i) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement**

**1. Statement**

Novelty (N)	Claims <b>2, 11-16, 21, 31, 36-38, 40-74, 80</b>	<b>YES</b>
	Claims <b>1, 3-10, 17-20, 22-30, 32-35, 39, 75-79</b>	<b>NO</b>
Inventive step (IS)	Claims <b>2, 11-16, 21, 31, 36-38, 40-74, 80</b>	<b>YES</b>
	Claims <b>1, 3-10, 17-20, 22-30, 32-35, 39, 75-79</b>	<b>NO</b>
Industrial applicability (IA)	Claims <b>1-80</b>	<b>YES</b>
	Claims <b>NONE</b>	<b>NO</b>

The present invention relates to taxane derivatives having a heterosubstituted-acetate substituent at C-7 and containing a sugar moiety and pharmaceutical composition containing them.

**2. CITATIONS AND EXPLANATIONS:****CITATIONS**

D1: EP 882732 B1 (ENSUIKO SUGAR REFINING COMPANY LIMITED et al.) 03 March 2004

D2: US 5767297 A (MANDAI et al.) 16 June 1998

**NOVELTY (N)**

D1 discloses taxoid derivatives containing a sugar moiety to increase physiological activity and water solubility - see Abstract, compounds 18 (identified as 7-S-paclitaxel, pages 12, 16 and Examples 2-4) and 19 (identified as 7-S-docetaxel, pages 12, 13, Example 6). This citation thus renders claims 1, 3-10, 17-20, 22-30, 32-35, 39 and 75-79 not novel.

D2 discloses taxoid derivatives containing a sugar moiety -see compound 18 (col 16 Tables 1 and 2) and compound 19 (cols 16, Example 6). Thus, D2 renders claims 1, 3-10, 17-20, 22-30, 32-35, 39 and 75-79 not novel.

Therefore the subject matter of claims 1, 3-10, 17-20, 22-30, 32-35, 39 and 75-79 is not new and does not meet the requirements of Article 33(2) of the PCT with regard to novelty.

None of the prior art documents discloses compounds comprising sugar moieties with the specific substitution pattern defined in claims 2, 11-16, 21, 31, 36-38, 40-74 and 80. Therefore, the subject matter of these claims is new and meets the requirements of Article 33(2) of the PCT with regard to novelty.

**INVENTIVE STEP (IS)**

Claims 1, 3-10, 17-20, 22-30, 32-35, 39 and 75-79 lack novelty and are therefore considered to lack an inventive step.

None of the prior art documents either individually or in combination obviously suggests modifying the sugar moiety to produce compounds with the substitution pattern defined in claims 2, 11-16, 21, 31, 36-38, 40-74 and 80 to a person skilled in the art of taxane derivatives. Therefore, the subject matter of these claims is not obvious and meets the requirements of Article 33(3) of the PCT with regard to inventive step.

**INDUSTRIAL APPLICABILITY (IA)**

The invention defined in the claims is considered to meet the requirements of Industrial Applicability under Article 33(4) of the PCT because it can be made by, or used in, industry.